Last reviewed · How we verify

CISATRACURIUM BESYLATE — Competitive Intelligence Brief

CISATRACURIUM BESYLATE (CISATRACURIUM BESYLATE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed cholinergic receptors Small molecule Live · refreshed every 30 min

Target snapshot

CISATRACURIUM BESYLATE (CISATRACURIUM BESYLATE). Cisatracurium besylate blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CISATRACURIUM BESYLATE TARGET CISATRACURIUM BESYLATE marketed cholinergic receptors 1995-01-01
Rocuronium Rocuronium Bromide Merck & Co. marketed Nondepolarizing neuromuscular blocking agent Cholinergic receptors at the motor end-plate 1994-01-01
SUCCINYLCHOLINE CHLORIDE SUCCINYLCHOLINE CHLORIDE marketed cholinergic receptors 1952-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CISATRACURIUM BESYLATE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1200641. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: